Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE-II: Upadacitinib in RA with inadequate response to MTX
NCT02066389Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (6 arms), sponsored by AbbVie Inc. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Mar 2014; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02066389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066389.